London-based healthtech company Abtrace has raised £2.1 million of seed funding in a round led by Faber and joined by Ganexa Capital.

The Abtrace technology aims to enable the management of long-term health conditions to move from a reactive, to a proactive process informed by data. 

WHY IT MATTERS

Abtrace has built an AI tool which can plug-into the Electronic Health Record (EHR) database and identify which tests or treatments a patient with a long-term health condition needs.

The software allows GPs and healthcare assistants (HCAs) to make informed decisions, automate key elements of disease monitoring, and ensure patients receive effective care. 

The system suggests actions based on an individual’s medical history as well as learning from a wider pool of data points, consequently prompting early interventions and spotting trends that might otherwise be missed. 

THE LARGER CONTEXT  

Abtrace has spent the last three years building its deep-learning platform in partnership with clinicians and the NHS. They had previously raised £2 million of pre-seed funding from EIT-Health’s Wild Card venture builder programme and UK Research & Innovation. 

ON THE RECORD

Abtrace co-founder and CEO, Dr Umar Naeem Ahmad, said: “As it stands, the management of long-term health conditions is an inefficient process for patients and their GP practice. It involves multiple appointments, duplication of tests, and tons of admin. It doesn’t deliver the best for patients and also wastes valuable NHS time and resources. Abtrace is working at the interface of AI and healthcare to transform this. 

“Our technology is incredibly simple to use - it takes each GP practice just 30 mins of training to get started - but delivers significant results. Through machine learning, we can scour millions of data points to give healthcare workers the information they need to provide the best for their patient. This means making each appointment as useful as possible, ensuring patients with long-term conditions get the support they need at the right time and, eventually, leveraging the technology to pick-up on the early signs of serious conditions such as cancer."